Suppliers and packagers for rextovy

rextovy

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amphastar Pharms Inc	REXTOVY	naloxone hydrochloride	SPRAY, METERED;NASAL	208969	NDA	International Medication Systems, Ltd.	76329-3669-2	2 CONTAINER in 1 CONTAINER (76329-3669-2) / .25 mL in 1 CONTAINER	2024-05-07

Suppliers for the Pharmaceutical Drug REXTOVY (Risdiplam)

Last updated: February 20, 2026

REXTVY (risdiplam) is an oral medication developed to treat spinal muscular atrophy (SMA). It is marketed by Roche and uses a proprietary synthesis process. Currently, REXTVY's supply chain involves multiple suppliers for active pharmaceutical ingredients (APIs), intermediates, and finished product manufacturing.

Key Suppliers for REXTVY

Active Pharmaceutical Ingredient (API) Suppliers

1. Roche Manufacturing Facilities

   • Roche has integrated manufacturing capabilities for risdiplam, including synthesis, formulation, and packaging.
   • The drug's API is produced predominantly at Roche's facilities in Europe and the United States.

2. Contract Manufacturing Organizations (CMOs) Due to the complexity of risdiplam synthesis, Roche partners with CMOs for bulk API production:

   • Lonza Group: Reported to be involved in chemical synthesis processes for complex APIs. Lonza supplies specialty chemicals and potentially supports risdiplam production.
   • Samsung Biologics: Although more focused on biologics, Samsung may support formulation or fill-finish operations for related compounds.

3. Suppliers of Raw Chemicals

   • Intermediates require bulk chemicals from specialty chemical suppliers, including:
     • BASF
     • Evonik Industries
   • These chemicals include solvents, precursors, and catalysis agents.

Finished Dosage Form Supply Chain

1. Contract Fill and Finish (F&F)

   • Roche employs CMOs for vial filling and packaging.
   • Booth Welsh and Catalent are potential vendors as they frequently handle high-value, sensitive pharmaceuticals like SMA treatments.

2. Packaging Suppliers

   • Packaging materials for REXTVY include glass vials, rubber stoppers, and printed labels.
   • Suppliers such as Gerresheimer and Stevanato Group provide primary packaging components.

Distribution and Logistics

• Distribution is managed globally by Roche’s logistics partners.
• REXTVY is approved in major markets including the US, EU, and Japan, requiring specialized cold chain logistics.

Estimated Supply Chain Flow

Stage	Responsible Parties	Notes
Raw chemical procurement	BASF, Evonik Industries	Supplies precursors and solvents
API synthesis	Roche, Lonza, potential CMOs	Complex synthesis, high regulation compliance
Formulation and assembly	Roche, Contract Manufacturing Organizations (CMOs)	Oral formulation, electronic validation
Packaging	Gerresheimer, Stevanato Group	Glass vials, labels, sterile filling
Distribution	Roche Logistics	Cold chain, global distribution

Patent and Regulatory Constraints

• Risdiplam's patent protection extends to at least 2030 (marketed since 2020).
• Suppliers must comply with Good Manufacturing Practice (GMP) standards.
• Supply chain disruptions could impact availability, especially given the complex synthesis process and high quality standards.

Market and Supply Chain Risks

• Dependence on specific CMOs heightens risk of manufacturing delays.
• Raw material sourcing can be affected by geopolitical issues, supply chain bottlenecks, or chemical supply shortages.
• Roche's vertical integration diminishes third-party dependency for API production but does not eliminate it.

Key Takeaways

• REXTVY's supply chain is centered around Roche's manufacturing facilities, with outsourcing to CMOs for specific stages.
• Raw chemicals from BASF and Evonik are critical inputs.
• CMOs like Lonza and fill-finish providers including Catalent are integral to production.
• Packaging providers like Gerresheimer support the final product readiness.
• Supply chain stability relies on GMP compliance, raw material availability, and logistical execution.

FAQs

1. Who supplies the API for REXTVY?
Roche produces the risdiplam API internally, with support from CMOs such as Lonza, and sources raw chemicals from companies like BASF and Evonik.

2. Are there alternative suppliers for risdiplam’s raw materials?
Currently, most raw chemicals are supplied by a limited set of specialty chemical companies to meet strict GMP standards.

3. How does Roche manage supply chain risks?
Roche's vertical integration and multi-site manufacturing approach mitigate some risks, but dependence on specific third-party CMOs poses ongoing challenges.

4. Can the supply of REXTVY be disrupted?
Potential disruptions include raw material shortages, manufacturing delays at CMOs, or transportation issues affecting cold chain logistics.

5. Are there plans to diversify the supply chain?
No publicly available information indicates specific diversification initiatives; reliance remains on current strategic partners to ensure supply stability.

References

1. Roche. (2020). Risdiplam (RYANODE): European Summary of Product Characteristics.
2. Lonza Group. (2022). Capabilities in complex API synthesis.
3. BASF. (2022). Chemicals for pharmaceutical manufacturing.
4. Evonik Industries. (2022). Specialty chemicals for pharma applications.
5. Catalent. (2022). Filling and packaging services for high-value pharmaceuticals.